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ABSTRACT
The renin-angiotensin-aldosterone system 
(RAAS) is one of the main regulators of 
blood pressure, renal hemodynamics, and 
volume homeostasis in normal physiology, 
and contributes to the development of renal 
and cardiovascular (CV) diseases. Therefore, 
pharmacologic blockade of RAAS constitutes 
an attractive strategy in preventing the 
progression of renal and CV diseases. This 
concept has been supported by clinical 
trials involving patients with hypertension, 
diabetic nephropathy, and heart failure, and 
those after myocardial infarction. The use 
of angiotensin II receptor blockers (ARBs) in 
clinical practice has increased over the last 
decade. Since their introduction in 1995, 
seven ARBs have been made available, with 




some with additional indications beyond 
blood pressure reduction. Considering that 
ARBs share a similar mechanism of action 
and exhibit similar tolerability profiles, it is 
assumed that a class effect exists and that 
they can be used interchangeably. However, 
pharmacologic and dosing differences 
exist among the various ARBs, and these 
differences can potentially influence their 
individual effectiveness. Understanding these 
differences has important implications when 
choosing an ARB for any particular condition 
in an individual patient, such as heart failure, 
stroke, and CV risk reduction (prevention 
of myocardial infarction). A review of the 
literature for existing randomized controlled 
trials across various ARBs clearly indicates 
differences within this class of agents. 
Ongoing clinical trials are evaluating the role 
of ARBs in the prevention and reduction of 
CV rates of morbidity and mortality in high-
risk patients.
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INTRODUCTION
Decisions surrounding antihypertensive 
treatment are influenced by the myriad of 
hypertension-induced (eg, heart failure [HF], 
ischemic heart or cerebrovascular disease, renal 
disease) and hypertension-associated (eg, type 2 
diabetes [T2D] or prediabetes, atherosclerosis) 
conditions, with each additional cardiovascular 
(CV) risk factor potentiating the risk in a given 
patient.1 Approximately 75% of the hypertensive 
population is estimated to have at least one 
additional CV risk factor (Figure 1).2 With respect 
to HF, regarded as the most rapidly escalating 
CV condition in North America,3 up to 90% 
of cases are preceded by hypertension1 and 
approximately one-third occur in conjunction 
with renal insufficiency.3 Overall, given that 
most patients with hypertension present with 
or develop comorbid CV and/or renovascular 
disease over their lifetime, blood pressure 
(BP) lowering is unlikely to be the sole goal of 
treatment in these patients in whom broader 
risk factor reduction is necessary for influencing 
long-term morbidity/mortality.
Angiotensin-converting enzyme inhibitors 
(ACEIs) and angiotensin II receptor blockers 
(ARBs) lower BP through blockade of the renin-
angiotensin-aldosterone system (RAAS), targeting 
the vasoconstrictive/antinatriuretic hormone 
angiotensin II.4 The RAAS has significance 
beyond hypertension given the putative role of 
angiotensin II in the pathogenesis of various CV 
(atherosclerosis, hypertensive left ventricular 
hypertrophy [LVH], HF- and atrial fibrillation 
[AF]-associated remodeling) and renal diseases.5,6 
The adverse effect of angiotensin II on the CV 
system is multifaceted (Figure 2), with the 
promotion of oxidative stress representing 
only one of several mechanisms by which it 
may influence the pathogenesis of target organ 
damage.6,7 The ARB class was introduced into 
clinical practice in 1995, when losartan was 
granted approval as an antihypertensive, and 
Figure 1. Coexistence of hypertension and cardiovascular/renal comorbidities (based on the National Health and 
Nutrition Examination Survey [NHANES] 2003-2004).2 CAD=coronary artery disease; CHF=congestive heart failure; 
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includes a total of seven agents approved for the 
treatment of hypertension (and, in some cases, 
for additional indications) (Table 1).8-14 A number 
of meta-analyses have calculated risk reductions 
for the ARB class of agents in areas outside of 
hypertension and, when taken together, suggest 
favorable effects in terms of preventing stroke 
and improving renal function and left ventricular 
(LV) mass, an uncertain risk/benefit profile in LV 
dysfunction and HF, and a potential increased 
risk for myocardial infarction (MI) in non-HF 
patients.15-22 Although conducting meta-analyses 
that capture multiple agents within a drug class 
is a common practice (with a tendency to also 
group data across ARBs and ACEIs to assess the 
broader RAAS inhibitor category) and may yield 
clinically interesting information, the results 
and conclusions should not be interpreted as 
implying an overall class effect. In the case of 
the ARBs, important differences exist across the 
pharmacologic and pharmacokinetic profiles of 
the individual agents, including their binding 
affinity and selectivity for the angiotensin II 
type 1 receptor (AT1).4 When given at their 
highest recommended doses for the treatment 
of hypertension, differences in BP lowering 
have been described.23 Clinically, the extent to 
which the AT1 binding affinity/selectivity-related 
differences within the ARB class influence BP 
control or long-term cardiorenal morbidity/
mortality is unknown.4
The vast randomized controlled trial (RCT) 
experiences during which ARB-associated effects 
on outcomes beyond BP control have been 
compared with those for non-ARB agents are 
captured in Table 2.24-105 Herein, key RCTs of 
ARBs are reviewed with the intent to identify 
any notable distinctions among losartan, the 
first ARB introduced to treatment, and the 
other ARBs (valsartan, candesartan, irbesartan, 
telmisartan, eprosartan, or olmesartan) in terms 
of effectiveness outside of BP control. Relevant 
RCT data across the various agents will be 
discussed as well as additional RCTs, irrespective 
of size, that directly compared losartan against 
another ARB.
CLINICAL OUTCOMES BEYOND BP 
LOWERING IN RCT
Atherosclerosis
Key RCT Data for Losartan
Data for the antiatherosclerotic effects 
of  losartan compared with another 
antihypertensive agent are only available 
from very small series, including a 57-patient 
Japanese study in which losartan led to no 
change in carotid intima-media thickness (IMT) 
Figure 2. Schematic representation of the central role 
played by angiotensin (Ang) type 1 receptor-mediated 
signaling in hypertension and cardiovascular disease 
progression.5 AT1R=angiotensin type 1 receptor; 
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among patients with hypertension (compared 
with a significant decrease with quinapril),24 
and a 13-patient Swedish study that showed 
significant improvement in endothelial function 
with losartan compared with atenolol in a 
hypertensive T2D population.25 Improvements in 
arterial stiffness have likewise been reported for 
losartan in small hypertensive and hemodialysis 
populations, with effects similar to an ACEI in 
both settings and effects greater than atenolol 
for hypertension.26-28
Key RCT Data for Other ARBs
In the AAA study (for definitions of trial 
name abbreviations see the Appendix at the end 
of this document), the reduction in IMT was 
significantly greater in amlodipine recipients 
than in ARB recipients, with a mean reduction 
of –0.046 mm compared with a mean increase 
of 0.080 mm in the ARB group (P<0.05).106 The 
authors noted that the lack of ARB effect on 
IMT was an unexpected finding, and that the 
difference in IMT reduction was not attributable 
to a difference in BP reduction because there was 
no significant difference between amlodipine 
and ARB treatment in that regard.106 Other 
published RCT data pertaining to the potential 
antiatherosclerotic effects of the individual ARBs, 
including parameters related to endothelial 
function and arterial stiffness, are summarized 
in Table 3.42,61,77,101,107 Results of the MITEC study, 
in which 209 patients with T2D and mild-to-
moderate essential hypertension were randomly 
assigned to receive candesartan 8-16 mg/day 
or amlodipine 5-10 mg/day (with addition of 
hydrochlorothiazide as needed), were recently 
published.107 MITEC, specifically designed with 
the primary objective of determining the relative 
effects of candesartan and amlodipine on carotid 
artery IMT, was originally designed as a 3-year 
study but was closed early because of a high 
rate of early withdrawals (primarily for lack of 
BP control). Analysis of the data showed similar 
reductions from baseline to month 12, month 
24, and last study visit in both treatment groups, 
with no statistically significant between-group 
differences at any time point. An encouraging 
finding was that more than 50% of patients 
per arm (56.5% and 59.0% of candesartan and 
amlodipine recipients, respectively; P=0.82) 
had carotid IMT regression from baseline to 
last study visit, supporting the theory that both 
Table 3. Examples of antiatherosclerotic effects in selected randomized controlled trials* of angiotensin II receptor blockers.
Agent Study Key findings
Valsartan MARVAL-2 Significant reduction in arterial stiffness with valsartan/HCTZ vs. amlodipine/HCTZ 
in hypertensive patients with albuminuria, which was independent of BP lowering42
Candesartan CENTRO Similar effects vs. enalapril on inflammatory markers of atherosclerosis in hypertensive 
patients with T2D61
MITEC Similar effects vs. amlodipine on carotid IMT in hypertensive patients with T2D107
Irbesartan SILVHIA Greater effectiveness vs. atenolol in reducing common carotid IMT in hypertensive 
patients with LVH77
Olmesartan EUTOPIA Greater effectiveness vs. placebo in significantly reducing vascular microinflammation 
in a hypertensive population with a high prevalence of atherosclerotic disease101
BP=blood pressure; HCTZ=hydrochlorothiazide; IMT=intima-media thickness; LVH=left ventricular hypertrophy; 
T2D=type 2 diabetes.
*In which the overall study population included >100 patients.
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agents affect the natural progression of carotid 
IMT in hypertensive patients with T2D.
Comparative Trials of Losartan Versus Other 
ARBs
The AAA study was a Japanese open-label 
RCT that compared the impact of amlodipine 
(2.5-5 mg/day) and ARB treatment (losartan, 
telmisartan, valsartan, or candesartan) on the 
IMT of the carotid wall in 104 hypertensive 
patients with T2D.106 Although losartan was a 
treatment option in the AAA study, only one 
patient received losartan. The results, as reported, 
provide no insight into the relative effects of the 
various ARBs because they only describe the ARB 
group as a whole.
Comment on the Antiatherosclerosis 
Experience With Losartan Versus Other ARBs
Favorable antiatherosclerotic effects have 
been documented for losartan and for other 
ARBs in small RCTs. However, large-scale RCT 
data are lacking and, therefore, preclude any 
conclusions supporting or refuting the role 
of ARBs in improving atherosclerosis-related 
outcomes. The relative effect of losartan versus 
the effect of other ARBs on parameters, such as 
carotid IMT, is unknown.
Left Ventricular Remodeling in Hypertensive 
Patients
Key RCT Data for Losartan
Benefits of losartan with respect to LVH 
regression were evident in the results of the 
primary analysis and a series of subanalyses of 
the landmark LIFE study. In this study, more 
than 9000 patients with previously treated or 
untreated hypertension and electrocardiography 
(ECG)-documented LVH received losartan 
50-100 mg/day or atenolol 50-100 mg/day. 
Hydrochlorothiazide was added as needed.29 
Publications derived from the LIFE study 
collectively support that losartan is significantly 
more effective than atenolol in not only reducing 
the composite of CV mortality/stroke/MI (primary 
endpoint), but also regressing LVH, as defined 
by the Cornell voltage-duration product and 
Sokolow-Lyon voltage criteria.29-32 After 1 year of 
treatment, patients with LV mass regression had 
significantly improved LV diastolic filling, an 
effect independent of BP lowering.108 In another 
substudy, involving 754 LIFE participants with 
serial LV mass determinations at baseline and 
after 12 and 24 months, significant reductions 
in LV mass and relative wall thickness were seen 
during the second year of the study (despite only 
minor BP reductions beyond those achieved 
during the first year), supporting the theory that 
the benefits of sustained BP control continue to 
accrue over at least 2 years of treatment despite 
a plateau in BP reduction.109
Key RCT Data for Other ARBs
Several other ARBs have been shown 
to improve hypertensive LVH relative to 
atenolol. In the SILVHIA study (n=115), similar 
BP reductions but significantly greater LV 
mass reductions were seen with irbesartan 
150-300 mg/day compared with atenolol 
50-100 mg/day (±hydrochlorothiazide and 
felodipine as needed).80,81 These regimens were 
also compared in the CVIP study (n=240), 
which showed significant reductions in 
LVH voltage for irbesartan 150-300 mg/day 
compared with atenolol 50-100 mg/day 
(with hydrochlorothiazide and amlodipine as 
needed) after 6 and 18 months of treatment. LV 
mass reduction was not evident in the overall 
population but was seen after 18 months in 
patients with the highest baseline LV mass index 
values, with a numerically but not significantly 
greater reduction for irbesartan in this subgroup.82 
Similarly, in a small RCT (n=69), treatment with 
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valsartan 80-160 mg/day (±hydrochlorothiazide) 
for 8 months reduced LV mass index to a 
significantly greater extent than did atenolol 
50-100 mg/day (±hydrochlorothiazide).46
There are other studies of ARB-induced 
effects on hypertensive LVH in which an 
agent other than atenolol was selected as 
the comparator regimen. For example, the 
effectiveness of candesartan in attenuating LVH 
in hypertensive populations was shown to be 
greater than that of amlodipine (in the CASE-J 
study [n=4703])63 and similar to that of enalapril 
(in the CATCH study [n=239]).62 Each study 
supported similar BP-lowering effectiveness 
when the study regimens were compared. Most 
recently, LVH-focused results were published 
together for the ONTARGET (n=25,620) and 
TRANSCEND (n=5926) studies, both of which 
were international RCTs that enrolled patients 
at high risk for CV disease without HF or LV 
dysfunction and included ECG-determined LVH 
assessments.91 Telmisartan was associated with a 
significant 24% reduction in the adjusted odds 
of LVH (P=0.0015) during the 5-year follow-up 
of the placebo-controlled TRANSCEND, with 
a significant 35% reduction in new-onset LVH 
(P=0.0001) and a nonsignificant 9% odds of 
LV regression (P=0.49) for those with baseline 
LVH. Within the latter group, the LV regression 
subset had a significantly greater systolic BP 
reduction than the LV persistence subset (6.8 
vs. 3.9 mmHg; P<0.0001). In ONTARGET, there 
was an 8% lower odds of LVH for telmisartan 
than ramipril that approached but did not 
reach significance (P=0.07).91 Comparisons 
of ARBs against amlodipine in small series in 
hypertension-associated LVH have produced 
variable findings. Whereas significantly greater 
LV mass reduction was seen with valsartan 
compared with amlodipine after 8 months 
in a Japanese study (along with significant 
reductions in monocyte-reactive oxygen 
species and C-reactive protein),47 no significant 
reduction was evident after 1 year of olmesartan 
or amlodipine in a more recently published 
US study.103
Comparative Trials of Losartan Versus 
Another ARB
A small Italian RCT evaluated losartan 
(50-100 mg/day) and valsartan (80-160 mg/day) 
on LVH and LV function in 32 patients with mild 
to moderate untreated essential hypertension 
and associated concentric LVH, known to 
confer a particularly high risk for CV disease.110 
Over 6 months, the regimens reduced systolic 
and diastolic BP to a similar degree. Significant 
reductions in LV mass index from baseline to 
the end of the 6-month study were observed 
with valsartan and with losartan; the effect for 
valsartan was significantly greater (P<0.05 vs. 
losartan). Significant improvements in predicted 
midwall fractional shortening and early 
peak/peak atrial velocity ratio occurred in 
both groups (no significant between-group 
differences), supporting the theory that the 
LV mass index reductions were associated 
with improvements in LV midwall systolic 
performance and in diastolic function in patients 
with concentric LVH.
Comment on the Hypertensive LVH Experience 
With Losartan Versus Other ARBs
The LIFE study of losartan showed favorable 
effects on hypertensive LVH. Encouraging 
data have been accumulating across various 
other ARBs. The results of one RCT of losartan 
compared with another ARB (valsartan) in 
hypertensive LVH have been published—a small 
study that showed a larger effect for valsartan 
on LV mass.110 However, it is insufficient for 
ascertaining clinically meaningful distinctions 
between these ARBs. Overall, with BP during 
treatment consistently noted to be similar 
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between groups in most of the comparative 
studies described here, the collective experience 
suggests that LVH improvements in ARB-treated 
patients with hypertension are independent of 
BP-lowering efficacy.
Secondary Prevention After MI
Key RCT Data for Losartan
Based on the OPTIMAAL study, losartan is not 
a suitable replacement for an ACEI after MI.33 
In this European study, nearly 5500 patients 
with confirmed acute MI and HF during the 
acute phase (or new Q-wave anterior infarction 
or reinfarction) were randomized to receive 
losartan (starting and target doses of 12.5 mg/day 
and 50 mg/day, respectively) or captopril 
(starting and target doses of 6.25 mg and 
50 mg three times daily, respectively), with 
all-cause mortality as the primary endpoint. 
At the study end, mean doses being received 
were losartan 45 mg/day and captopril 44 mg 
three times daily. Regarding BP assessment, 
measurements were taken for 6 hours after the 
first dose and as part of the study follow-up, 
with significantly greater BP reduction seen 
during the first 2 hours with the starting dose 
of captopril 6.25 mg compared with losartan 
12.5 mg. Specifically, at 1 hour post-first-dose, 
mean BP was 114/66 mmHg for captopril 
versus 119/69 mmHg for losartan (P<0.0001). 
The authors noted that BP was otherwise 
similar between the two groups. After a 2.7-
year mean follow-up, the mortality rate was 
18% in the losartan group and 16% in the 
captopril group, translating into a 13% greater 
risk for death with losartan that approached 
significance (P=0.07).
Key RCT Data for Other ARBs
Valsartan has been shown to affect post-MI 
LV function to the same degree as an ACEI, 
supporting its approval for this indication. 
The VALIANT study, a three-arm comparison 
of valsartan (160 mg twice daily), captopril 
(50 mg three times daily), or valsartan (80 mg 
twice daily) plus captopril (50 mg three times 
daily) in nearly 15,000 patients with MI with 
complicating HF and/or LV dysfunction, 
showed no significant difference across the 
arms with respect to the primary endpoint 
of CV morbidity/mortality. ARB or ACEI 
monotherapy, however, was advantageous over 
combination treatment in terms of adverse 
events.48 Per noninferiority analyses, valsartan 
was at least as effective as captopril in terms 
of preventing CV morbidity/mortality. A subset 
of the VALIANT participants were enrolled into 
the VALIANT Echo substudy (n=610), which 
found that the three study regimens also were 
similarly effective in improving ventricular 
structure and function over the 20-month 
post-MI period.49
Recently published results of another RCT 
of valsartan compared with ACEI post-MI 
treatment, the T-VENTURE study, are consistent 
with those of VALIANT.50 In this Japanese study 
that enrolled 256 patients with first acute 
MI, valsartan (dosed to a target of 160 mg/
day) was as effective as an ACEI (one of seven 
agents) in protecting against LV dysfunction, 
as determined by left ventriculography 
repeated at 6 months after MI.50 Another 
Japanese Study known as E-COST evaluated 
candesartan compared with other non-ARB/
ACEI antihypertensive treatment on CV 
morbidity/mortality in 2048 patients with 
essential hypertension, showing a significant 
57% reduction in MI (P<0.05). However, 
this finding was largely influenced by a 76% 
reduction among patients with no history of a 
CV event, with an insignificant 26% reduction 
among patients who experienced a previous MI 
or stroke.64
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Comment on the Secondary Prevention Post-
MI Experience With Losartan Versus Other 
ARBs
Available RCT post-MI data for losartan, 
from a single trial, do not support benefits in 
this setting. Valsartan has been shown to be 
as effective as an ACEI in improving post-MI 
LV function and, therefore, has regulatory 
approval for this use. The relative post-MI 
effects of losartan compared with the other ARBs 
are unknown.
Stroke
Key RCT Data for Losartan
In the LIFE study, stroke was included as 
part of the primary composite endpoint, along 
with MI and CV mortality rate.29 The ability of 
losartan to reduce the incidence of stroke by 
25% (5% vs. 7% with atenolol; P=0.001) ranks 
among the most clinically notable findings of 
the LIFE study.29 Stroke prevention was also 
evident in a subanalysis of the LIFE trial that 
focused on a subset of 6886 patients without 
known vascular disease.111 As in the overall 
population, BP reductions were similar in this 
subset regardless of treatment with losartan 
or atenolol. However, with losartan there was 
a significant 19% reduction in the composite 
endpoint of CV death, stroke, and MI (P=0.008), 
which included an even greater 34% reduction 
in incident stroke (P<0.001).111 Subanalysis by 
race showed that black individuals treated with 
losartan were actually at increased risk for stroke 
events than black individuals who received 
atenolol (unadjusted hazard ratio, 1.99), and this 
approached statistical significance (P=0.051).34 
Another LIFE subanalysis provided information 
for specific stroke subtypes, with a significant 
35% reduction for losartan in terms of fatal 
stroke (P=0.032) and significant 27% reductions 
for the ischemic (P=0.001) and atherothrombotic 
(P=0.002) subtypes.34 Incidences of embolic, 
hemorrhagic, and other/unclassified stroke 
were not significantly different between the 
two groups. The difference in recurrent stroke, 
however, was significant (P=0.017) with 
26 losartan recipients compared with 46 atenolol 
recipients experiencing two or more incident 
strokes during the study follow-up.
Key RCT Data for Other ARBs
As in LIFE,29,34 most of the trials that 
evaluated stroke prevention for the other ARBs 
(Table 4) included incident stroke within the 
primary composite endpoint of CV morbidity/
mortality, an exception being the PRoFESS 
(n=20,332) secondary prevention study of 
telmisartan. Telmisartan had no impact on the 
primary endpoint of recurrent stroke after a 2.5-
year mean follow-up in PRoFESS93 or on the 
composite component of stroke in the placebo-
controlled TRANSCEND (n=5926).92
Encouraging stroke prevention data have 
also been reported for valsartan,51,52 eprosartan 
(specifically as secondary prevention),104 and 
candesartan.64,65 For example, in the Jikei 
Heart Study, valsartan 40-160 mg/day or a 
non-ARB was added to conventional treatment 
in 3081 Japanese patients with hypertension, 
coronary heart disease, and/or heart failure.51 
The addition of valsartan lowered the 
incidence of stroke or transient ischemic attack 
by 40%, compared with non-ARB treatment 
(P=0.028). Similarly, in the KYOTO HEART 
Study (n=3031), the addition of valsartan 
40-160 mg/day to existing treatment in 
Japanese patients with high-risk hypertension 
reduced the incidence of stroke or transient 
ischemic attack by 45%, compared with non-
ARB treatment (P=0.015).52 In the placebo-
controlled SCOPE trial, in nearly 5000 patients 
70-89 years of age with mild to moderate 
hypertension, candesartan 8-16 mg/day was 
Adv Ther (2010) 27(5):257-284. 267
associated with a significant 28% reduction 
in nonfatal stroke (P=0.04) and a 24% all-
stroke reduction of borderline significance 
(P=0.056).65 In a subanalysis of patients with 
isolated systolic hypertension, there was a 
significant 42% reduction in fatal/nonfatal 
stroke (P=0.05).66 In the aforementioned 
E-COST evaluation of candesartan compared 
with other non-ARB/ACEI antihypertensive 
treatment in 2048 patients with essential 
hypertension, there was a significant 39% 
reduction (5.8% vs. 9.4%; P<0.05) in stroke 
incidence for candesartan overall that was 
driven by the 61% reduction (18.3% vs. 46.9%; 
P<0.01) in patients with a CV history of stroke 
or MI.64 From a primary prevention standpoint, 
however, the incidence of stroke was increased 
among those who received candesartan instead 
of the conventional treatment (3.5% vs. 1.2%; 
P value not reported).
Table 4. Examples of stroke-preventative effects in selected randomized controlled trials* of angiotensin II receptor blockers.
Agent Study Key findings
Losartan LIFE Overall stroke: significant stroke reduction vs. atenolol (25%; P=0.0010),29 with 
significant reductions in a subset without clinical vascular disease (34%; P<0.001)111 
and in ischemic (27%; P=0.001), atherothrombotic (27%; P=0.002), and fatal  
(35%; P=0.032) stroke in a subanalysis of specific subtypes34
Secondary prevention: significant reduction (n=26 vs. n=46; P=0.017) in subtype-
focused analysis34
Valsartan Jikei Heart Study Overall stroke: significant reduction vs. non-ARB regimens (40%; P=0.028) in stroke 




Overall stroke: significant reduction vs. non-ARB regimens (45%; P=0.015) in 
stroke or transient ischemic attack in patients with hypertension at high risk for 
cardiovascular events52
Candesartan SCOPE Overall stroke: significant reduction vs. placebo (28%; P=0.04) in nonfatal stroke in 
elderly hypertensive patients,65 with significant all-stroke reduction in a subset with 
isolated systolic hypertension66
E-COST Primary prevention: no significant stroke reduction vs. conventional antihypertensive 
treatment, with a 29% increased risk with candesartan in patients without history of 
stroke or MI64
Secondary prevention: significant stroke reduction for candesartan vs. conventional 
antihypertensive treatment in patients with past stroke or MI (61%; P<0.01)64
Telmisartan PRoFESS Secondary prevention: no significant recurrent stroke reduction (primary endpoint) 
vs. placebo when initiated within 90 days after ischemic stroke93
TRANSCEND Overall stroke: no significant stroke reduction vs. placebo in ACEI-intolerant patients 
with cardiovascular disease or diabetes/end-organ damage92
Eprosartan MOSES Secondary prevention: significant reduction vs. nitrendipine (25%; P=0.026) in fatal/
nonfatal cerebrovascular events104
ACEI=angiotensin-converting enzyme inhibitor; ARB=angiotensin II receptor blockers; MI=myocardial infarction.
*In which the overall study population included >100 patients.
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Comment on Stroke Prevention Experience 
With Losartan Versus Other ARBs
Losartan lowered the risk for first stroke in 
the LIFE study, an effect that has since been 
documented for valsartan (in Jikei Heart and 
KYOTO HEART) and candesartan (in SCOPE 
but not in E-COST). In terms of secondary 
prevention, losartan appears to be effective 
(also per LIFE); however, the experiences with 
the other ARBs have been mixed. For losartan, 
stroke reduction in hypertensive patients with 
LVH is an approved indication. The relative 
effectiveness of losartan compared with other 
ARBs for primary or secondary stroke prevention 
is unknown.
Heart Failure
Key RCT Data for Losartan
The ELITE trial, a 48-week study in 722 elderly, 
ACEI-naive patients with symptomatic HF, 
demonstrated a 9.4% rate of death and/or 
HF-related hospitalization for losartan (50 mg/day) 
compared with 13.2% for captopril (50 mg three 
times daily).35 Although this 32% risk reduction 
was not significant (P=0.075), there was a 
significant difference in the all-cause mortality 
rate: 4.8% for losartan compared with 8.7% for 
captopril, a 46% reduced risk of death (P=0.035) 
that appeared to be largely influenced by a 
reduction in the occurrence of sudden cardiac 
death (1.4% vs. 3.8%). In the ELITE ventricular 
function substudy, in which 29 patients 
underwent radionuclide ventriculography 
at baseline and after 48 weeks, losartan and 
captopril; prevented LV dilation to a similar 
degree, whereas only captopril induced reverse 
remodeling.36 The intriguing survival benefit 
of losartan in ELITE prompted the design of a 
larger RCT of losartan compared with captopril 
to further assess mortality rate in a similar 
HF population (ELITE II [n=3152]). Unlike in 
ELITE, however, the advantages for losartan in 
ELITE II pertained only to adverse event-related 
discontinuation rates, thereby suggesting that 
the between-group mortality rate differences 
in ELITE were likely the product of chance.37 
No differences between the two groups were 
apparent in the main ELITE II efficacy results 
(ie, all-cause mortality [primary endpoint], 
sudden death or resuscitated arrest, or all-cause 
mortality or hospitalization)37 or in a subsequent 
report focused on HF-related outcomes (mortality, 
hospitalizations, discontinuations, change in 
New York Heart Association [NYHA] class, and 
quality of life [with significant improvements in 
the latter two parameters in both groups]).112
Key RCT Data for Other ARBs
Candesartan has shown favorable effects 
on ventricular function in patients with HF, 
initially in the RESOLVD study (n=768) in which 
the combination of candesartan and enalapril 
showed promise in preventing LV remodeling 
among patients with NYHA class II-IV congestive 
HF (CHF).67 
The CHARM program consisted of three 
concurrently conducted placebo-controlled 
RCTs in the following three symptomatic HF 
populations, based on LV ejection fraction 
(LVEF) and concurrent treatment: (1) patients 
with LVEF >40% (CHARM-Preserved); (2) LVEF 
≤40% receiving an ACEI (CHARM-Added); 
(3) and LVEF ≤40% not receiving an ACEI owing 
to intolerance (CHARM-Alternative). A series of 
reports based on the overall CHARM program 
(n=7599), for which the primary outcome was 
all-cause mortality (23% candesartan vs. 25% 
placebo; P=0.055 [unadjusted] or P=0.032 
[covariate adjusted]), support significant benefits 
for candesartan 32 mg/day in improving the rates 
of CV death and HF-related hospitalization,68 
sudden death and death from worsening HF,69 
and NYHA functional class.70 In a combined 
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analysis of CHARM-Added and CHARM-
Alternative, all-cause mortality, CV death, and 
HF hospitalizations were significantly lower for 
candesartan than for placebo in HF patients 
with LVEF ≤40%.71 Improvements in the primary 
outcome established for the individual trials 
(ie, CV death or unplanned hospitalization for 
management of worsening CHF) were achieved in 
CHARM-Added, including the subset of patients 
also receiving a beta-blocker,72 and CHARM-
Alternative73 but not in CHARM-Preserved.74 
(However, this third trial in patients with LVEF 
>40% showed fewer HF-related hospitalizations 
among candesartan recipients.)
The Val-HeFT study (n=5010) was designed 
to determine whether reductions in morbidity/
mortality rate could be achieved by adding 
valsartan (target dose 160 mg twice daily) 
compared with placebo to an existing HF drug 
regimen (93% of patients were on ACEIs, 86% 
diuretics, 67% digoxin, and 35% beta-blockers), 
using coprimary endpoints of mortality alone 
or with morbidity (ie, cardiac arrest with 
resuscitation, HF-related hospitalization, or 
outpatient administration of intravenous 
inotropic or vasodilator drugs for ≥4 hours).53 
Mortality rate was nearly identical in the 
valsartan and placebo groups, at 19.7% and 
19.4%, respectively. However, the combined 
mortality/morbidity outcome improved 
significantly among valsartan recipients to 
28.8% compared with 32.1% with placebo, a 
significant 13% risk reduction (P=0.009). Within 
the mortality/morbidity composite, there was 
a notable difference in the rate of HF-related 
hospitalization: 13.8% compared with 18.2% 
with placebo. In the subset of patients who were 
not treated with an ACEI (n=366), regardless of 
beta-blocker use, valsartan treatment reduced 
the risk of morbidity/mortality by 44% and 
the risk of mortality by 33% compared with 
placebo.53 However, in the subgroup receiving 
valsartan, an ACEI, and a beta-blocker, mortality 
was significantly increased by approximately 
40% (P=0.009) and there was a trend toward 
higher morbidity/mortality (nonsignificant 
20% approximate increase; P=0.10). This finding 
suggested a potential negative effect of blocking 
multiple neurohormonal systems in patients 
with HF.
The reason for the difference between 
CHARM-Added and Val-HeFT with respect to 
the subset receiving triple therapy with an ARB, 
ACEI, and beta-blocker is not altogether clear. 
There are several differences between CHARM 
and Val-HeFT that could have influenced the 
results and may explain the differences between 
their outcomes. Compared to CHARM, Val-HeFT 
involved mainly NYHA class II patients and 
utilization of digoxin was higher while beta-
blocker use was much lower (35%). CHARM 
involved more patients with NYHA class III 
disease, diabetes, and ischemic heart disease, 
and more patients receiving beta-blockers, 
spironolactone, and diuretics. The Val-HeFT 
echocardiographic study, which focused on 
measurements of LV internal diastolic diameter 
and LVEF, showed significant improvements 
in both parameters when valsartan was 
coadministered with an ACEI (without beta-
blocker) or beta-blocker (without ACEI), but not 
when added to ACEI/beta-blocker combination 
treatment.54 In patients who did not receive 
either an ACEI or a beta-blocker, treatment with 
valsartan significantly improved LV internal 
diastolic diameter and nonsignificantly improved 
LVEF. An additional analysis of the Val-HeFT 
echocardiographic data determined that the 
patients with the most severe LV remodeling 
derived the greatest benefit from valsartan.113 
More recently, the placebo-controlled 
I-PRESERVE study (n=4128) failed to show 
improved outcomes for irbesartan 300 mg/day 
in patients with NYHA class II-IV HF with an 
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LVEF ≥45%.83 Although RCT data are also 
available for eprosartan and telmisartan, they 
represent smaller, shorter-term studies that do 
not provide insight into the long-term benefits 
of these ARBs in patients with HF.94,105
Comment on the HF Experience With 
Losartan Versus Other ARBs
Although ELITE suggested a role for losartan 
in patients with HF, no benefit was seen in the 
confirmatory ELITE II study, and results do not 
favor the use of losartan as a substitute to an 
ACEI. Recent data show that, in ACEI-intolerant 
patients, increased-dose losartan has a greater 
effect on reducing HF-related hospitalization 
than the conventional antihypertensive dose. 
The positive findings of RCTs of valsartan (Val-
HeFT) and candesartan (CHARM) prompted 
their approval for use in patients with HF. The 
extent to which losartan reduces HF-related 
morbidity/mortality rates relative to the other 
ARBs is unknown.
Atrial Fibrillation
Key RCT Data for Losartan
Data from the LIFE study support that in 
patients with hypertension and ECG LVH, 
losartan offers additional advantages over 
atenolol in the primary prevention of AF.38 
Among losartan recipients, there was a 33% 
lower incidence of new-onset AF, a significant 
effect (P<0.001) that was independent of 
other known risk factors incorporated into 
the multivariate analysis.38 A subsequent 
subanalysis found that the effects of losartan 
in reducing new-onset AF were associated with 
a reduction in LVH and independent of BP 
lowering.114 To better characterize the effects of 
RAAS blockade in the secondary prevention of 
AF, without the confounding influence of other 
comorbidities, Yin et al. randomly assigned 
177 patients with lone paroxysmal AF to receive 
amiodarone alone, amiodarone plus losartan 
50-100 mg/day, or amiodarone plus the ACEI 
perindopril 2-4 mg/day.115 In these groups, the 
incidences of recurrent AF within 24 months 
after randomization were 41%, 19%, and 24%, 
respectively, with significant advantages for 
both combinations compared with amiodarone 
in Kaplan-Meier analysis (P=0.006 for losartan/
amiodarone; P=0.04 for perindopril/amiodarone) 
and a Cox proportional hazards model (in 
which the relative risks were 0.36 [P=0.006] 
and 0.39 [P=0.008], respectively). Significant 
reductions in left atrial diameter were also seen 
with both combinations relative to amiodarone 
monotherapy (P<0.001).
Key RCT Data for Other ARBs
AF-preventing effects have been reported for 
several other ARBs. In an RCT in 154 patients 
with a history of persistent AF assessed for 
recurrence during the 2 months after electrical 
cardioversion, irbesartan 150-300 mg/day 
plus amiodarone was associated with an 85% 
2-month probability of maintaining sinus 
rhythm compared with 63% with amiodarone 
alone.85 ARB use was identified as the only 
significant factor for maintaining sinus rhythm 
on multivariate analysis, translating into a 65% 
lower risk for recurrent AF than amiodarone 
alone (P=0.018) and an 81% reduction in a 
Cox proportional model that adjusted for 
factors such as diabetes, bundle-branch block, 
and AF duration (P=0.031). At last follow-up, 
after a median of 254 days, the probabilities of 
maintaining sinus rhythm were 80% and 56% 
for irbesartan/amiodarone and amiodarone, 
respectively. Valsartan subsequently was found 
to affect AF based on a post-hoc subanalysis 
of Val-HeFT that evaluated incident AF after 
add-on treatment with valsartan (target dose 
160 mg twice daily) or placebo in patients 
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with class II-IV HF.56 In 4395 patients with 
sinus rhythm at baseline, AF was reported 
as an adverse event in 5.1% of valsartan 
recipients compared with 8.0% of placebo 
recipients, translating into a highly significant 
37% relative risk reduction on multivariate 
analysis (P=0.0003). The placebo-controlled 
GISSI-AF trial (n=1422) was subsequently 
designed specifically to evaluate the effects 
of add-on valsartan (target dose 320 mg/day) 
on the rate of recurrent AF.55 Recently published 
results revealed no effect for valsartan on the 
primary outcome of first AF recurrence at 1 year 
(51% vs. 52% for placebo; adjusted hazard 
ratio 0.97; P=0.73) or the rate of multiple AF 
recurrences (27% vs. 28% for placebo; adjusted 
odds ratio 0.89; P=0.34). The results of GISSI-AF 
were consistent with those previously reported 
for the smaller CAPRAF study (n=171), in which 
postconversion candesartan 16 mg/day was no 
more effective than placebo in reducing the 
6-month rate of recurrent AF among patients 
not receiving antiarrhythmic treatment.75
Comment on the AF Prevention Experience 
With Losartan Versus Other ARBs
Data for losartan as AF prevention are limited, 
yet more favorable overall than those for the 
other ARBs, considering that negative results have 
been reported for several ARBs when evaluated 
specifically in patients with AF. Combining 
losartan or irbesartan with amiodarone appears 
to warrant further study in the prevention of 
recurrent AF. The relative effects of losartan 
compared with other ARBs as primary or 
secondary AF prevention are unknown.
Renoprotection
Data from RCTs detailing the renoprotective 
effects of ARBs are summarized in Table 5.39-42,57-
61,76,86-88,96-99,116,117
Key RCT Data for Losartan
Preventing nephropathy in patients 
with T2D is one of the approved indications 
for losartan. The results of the RENAAL 
study, published in 2001, clearly showed 
renoprotective benefits for losartan in patients 
with T2D and nephropathy (Table 5).39 In 
RENAAL, 1513 patients received losartan 
50-100 mg/day or placebo, in conjunction 
with conventional antihypertensive treatment, 
and were followed up for a mean of 3.4 years. 
The losartan group had a 16% risk reduction 
(P=0.02) for the primary composite endpoint 
of doubling of baseline serum creatinine (SCr), 
end-stage renal disease (ESRD), or death. The risk 
reductions for the individual renal outcomes 
within the composite were also significant 
(25% for SCr doubling [P=0.006] and 28% for 
ESRD [P=0.002]), whereas mortality rate was 
similar regardless of whether patients received 
losartan or placebo. The authors noted that 
differences in trough BP (albeit slightly lower 
among the losartan recipients) did not explain 
the renoprotective effects that were observed in 
RENAAL, with minimal change in the primary 
composite endpoint after adjusting for BP.39 A 
number of smaller studies collectively suggest 
that the renoprotective effects of losartan 
treatment extend to populations beyond 
T2D nephropathy and are not attributable 
to the antihypertensive effects of losartan 
(Table 5).40,41
The ROAD study (n=360) of ARB or ACEI 
monotherapy was unique in that it evaluated 
doses of losartan and benazepril in patients 
with nondiabetic proteinuria and chronic 
renal insufficiency titrated based on urinary 
protein excretion, SCr, and potassium levels, 
with a median of 100 mg/day for losartan 
(range 50-200 mg/day) and 20 mg/day for 
benazepril (range 10-40 mg/day).41 By tailoring 
treatment according to optimal antiproteinuric 
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effectiveness, losartan and benazepril significantly 
reduced the occurrence of SCr doubling, ESRD, 
or death by 53% (P=0.022) and 51% (P=0.028), 
respectively. There were no efficacy-related 
differences between losartan and benazepril at 
the conventional or antiproteinuric doses, and 
no dose-related increases in BP reduction or in 
adverse events.
Key RCT Data for Other ARBs
Much data support the theory that irbesartan 
(the only ARB other than losartan approved for 
preventing nephropathy in T2D) and several 
other ARBs (ie, valsartan, candesartan, and 
telmisartan) are renoprotective in patients 
with T2D (Table 5),57,58,61,86,87,96,99,116,117 more so 
than amlodipine and similar to ACEIs based 
on active-controlled evaluations.57,58,86,99 At 
the recommended target dose of 300 mg/day, 
irbesartan reduced the risk for SCr doubling/
ESRD/death by 20% compared with placebo 
(P=0.02) and 23% compared with amlodipine 
(P=0.006) in the IDNT study (n=1715)86,87 and the 
onset of diabetic nephropathy by 70% compared 
with placebo (P<0.001) in the IRMA-2 study 
(n=590).87 The IDNT and IRMA-2 studies both 
were conducted in hypertensive patients with 
T2D and determined that the renoprotection 
afforded by irbesartan was independent of 
BP lowering.86,87
Reported RCT comparisons involving the 
other ARBs have shown renoprotective effects in 
T2D populations (Table 5). In the MARVAL study 
(n=332), for example, mean urinary albumin 
excretion rate improved by 44% at 24 weeks in 
patients treated with valsartan 80-160 mg/day, 
compared with only 8% in patients who received 
amlodipine 5-10 mg/day (P<0.001).57 An 
exception to the favorable results obtained with 
most ARBs was reported in a pooled analysis of 
the three placebo-controlled studies within the 
DIRECT program.76 Although the overarching 
objective of the DIRECT program was to 
evaluate the effect of candesartan 32 mg/day 
on retinopathy in patients with diabetes 
(type 1 or 2),  microalbuminuria was 
designated as a primary endpoint for the 
pooled analysis. After a 4.7-year median 
follow-up in the pooled analysis (n=5231), 
there was a nonsignificant 5% reduction 
(P=0.60) in incident microalbuminuria among 
candesartan recipients compared with placebo 
recipients. The authors proposed that the lack 
of renoprotection may have been influenced 
in part by the dominance of normotensive 
patients (with a corresponding low vascular 
risk) in this series of studies.76 In this regard, 
although the majority of data support that 
ARB-induced renoprotection is not a BP-related 
phenomenon, there are reports in which 
improved renal outcomes have been associated 
with improved BP control.117
Overall, RCTs of valsartan, irbesartan, and 
telmisartan in nondiabetic renal disease have 
yielded mixed findings. The 133-patient VALERIA 
study found that the combination of valsartan 
320 mg/day plus lisinopril 20 mg/day led to 
significant improvements in albuminuria and the 
rate of microalbuminuria resolution over those 
seen with single-agent valsartan 320 mg/day 
or lisinopril 40 mg/day.59 On the contrary, 
in the aforementioned ONTARGET study in 
more than 25,000 patients with atherosclerotic 
vascular disease or diabetes-related end-organ 
damage, there was an unexpected worsening 
in the primary composite outcome (dialysis/
SCr doubling/death) with the combination of 
telmisartan 80 mg/day plus ramipril 10 mg/day 
compared with either agent alone (hazard 
ratio 1.09; P=0.037).98 The placebo-controlled 
IMPROVE (n=405) and telmisartan TRANSCEND 
studies did not show renal benefits for ARB 
treatment in patients without microalbuminuria 
at high risk for CV disease.88,97
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Comparative Trials of Losartan Versus 
Another ARB
Recognizing that differences in AT1 antagonism 
across the ARBs may confer renoprotective 
differences, a small Japanese RCT evaluated 
the relative merits of perindopril, trandolapril, 
candesartan, and losartan in 62 hypertensive 
patients with chronic renal disease, focusing on 
proteinuria and urinary nitrite/nitrate (NOx) 
excretion over 96 weeks.118 The four agents were 
similar in their BP reductions and lack of effect on 
creatinine clearance. When comparing the ARBs, 
candesartan was more effective than losartan in 
reducing proteinuria and was associated with 
sustained antiproteinuric activity during the 
study (which was not the case for losartan), with 
a significant difference between candesartan and 
losartan at study end. Substantial increases in 
urinary NOx excretion were likewise seen with 
all agents, except losartan. Overall, these results 
suggested that the antiproteinuric effects of 
losartan are less pronounced than those achieved 
with an ACEI or candesartan.
Losartan is the only ARB with established 
uricosuric activity.119 Accordingly, the results of 
a South African RCT of the effects of losartan 
compared with candesartan on uric acid, 
renal function, and fibrinogen in 59 patients 
with hypertension and diuretic-associated 
hyperuricemia pointed to advantages in the 
losartan arm.119 Although BP reductions were 
similar in the two groups, the losartan group 
experienced a significant reduction in uric 
acid levels after 24 weeks and significantly 
fewer patients had a SCr increase of 10%, 
compared with the candesartan group (14.2% 
vs. 44%; P<0.02).
Hypothesizing that an ARB with high 
lipophilicity and long half-life (telmisartan) 
would be more effective in reducing proteinuria 
than a low lipophilicity ARB with a shorter half-
life (losartan), the AMADEO study (n=860) was 
conducted using the 52-week difference in the 
urinary protein/creatinine ratio as the primary 
endpoint.116 This variable decreased significantly 
(P<0.0001) from baseline to week 52 in both 
groups; however, the reduction was significantly 
more pronounced with telmisartan than with 
losartan (29.8% vs. 21.4%; P=0.03), as were 
the reductions in several secondary outcomes, 
including CV morbidity/mortality (21 events 
vs. 37 events; P=0.037) and all-cause mortality 
(two events vs. 13 events; P=0.007). A 4.2 mmHg 
difference in systolic BP was seen at week 8, 
favoring the telmisartan group; however, 
differences were much less pronounced at all 
subsequent time points.
Comment on the Renoprotection Experience 
With Losartan Versus Other ARBs
Losartan and irbesartan have an established 
renoprotective role in patients with T2D 
nephropathy. Experiences with these and 
other ARBs have been consistent in diabetic 
renal disease but not in nondiabetic renal 
disease. Some limited evidence from RCTs 
suggests greater antiproteinuric effects for 
candesartan (in chronic renal disease) and 
telmisartan (in T2D nephropathy) than with 
losartan, which has uricosuric effects that 
may benefit patients with hyperuricemia-
associated renal disease. The relative impact 
of losartan compared with other ARBs as 
renoprotection in diabetic and nondiabetic 
renal disease is unknown.
Although not the focus of this article, 
numerous RCTs also support the positive 
effects of RAAS blockade on the prevention of 
diabetes (eg, LIFE, SCOPE). Elliott and Meyer 
conducted a meta-analysis that included 
22 RCTs and more than 143,000 patients, 
most of whom had hypertension.120 The 
antihypertensive class least associated with 
incident diabetes was the ARBs, with an odds 
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ratio of incident diabetes of 0.57, compared 
with diuretics (P<0.0001). Further assessment 
of the role of ARBs in preventing diabetes was 
addressed in the NAVIGATOR study. This is 
a large multicenter randomized study with 
the goal of evaluating the effects of valsartan 
or nateglinide treatment, individually or 
combined, on reducing the risk for T2D or 
CV events in patients with impaired glucose 
tolerance.121 Recently published results 
support a modest but statistically significant 
14% reduction in incident T2D with a 5-year 
course of valsartan versus placebo (33.1% vs. 
36.8%; P<0.001) but no CV event reduction 
(14.5% vs. 14.8%; P=0.43), with improvement 




The clinical practice considerations taken 
from the trials discussed for callout are 
as follows:
Efficacy and safety results of any given trial •	
of one particular ARB may not be easily 
extrapolated to another ARB.
Switching from one ARB to another solely on •	
the basis of cost, irrespective of the clinical 
trial data available for the specific agents, 
can have adverse economic implications.
For effects beyond BP, there is no accepted •	
method for determining which dose of 
an unstudied ARB might provide similar 
effectiveness compared with an ARB that has 
been proven effective in an RCT (ie, there is 
no dose-equivalency map).
When treating patients, clinicians should •	
design a treatment plan that takes into 
consideration all comorbidities/risk factors 
and choose the ARB that is proven effective, 
based on RCTs, in their management.
Losartan was the first commercially available 
ARB and therefore the first to be available on a 
generic basis. Although in today’s environment 
of increasing healthcare costs, economic 
factors play a major role in determining the 
type of antihypertensive agent prescribed, it 
is important to also consider clinical evidence 
from large-scale RCTs in the selection process. 
Regarding the ARB class of agents, efficacy and 
safety results of any given trial of one particular 
agent may not be easily extrapolated to another 
ARB. Switching from one ARB to another solely 
on the basis of cost, irrespective of the clinical 
trial data available for the specific agents, can 
have adverse economic implications.124 For 
example, in an economic analysis of patients in 
whom a switch from valsartan to another ARB 
was prompted by a copayment increase, this 
nonmedical reason for switching increased the 
ARB discontinuation rate, hypertension-related 
outpatient visits, and the number of days of 
hypertension-related hospitalization, thereby 
increasing healthcare resource use and costs.124 
Although RCTs showed differences between 
ARBs in regard to slowing down the progression 
in organ damage, data concerning prevention of 
CV morbidity/mortality are lacking.
Another complicating issue is that, for effects 
beyond BP, there is no accepted method for 
determining which dose of an unstudied ARB 
might provide similar effectiveness compared 
with an ARB that has been proven effective in 
an RCT (ie, there is no dose-equivalency map). 
Although BP control is clearly an important 
goal of ARB treatment, dosing decisions become 
more complex when other comorbidities are 
factored into the equation. In some situations 
the correlation between BP control and organ 
protective effects is low, such as in patients with 
HF (eg, patients with normal BP in Val-HeFT 
derived benefit from valsartan treatment) or 
normotensive patients with diabetic nephropathy 
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(eg, the IRMA-2 study showed benefit from 
increasing the irbesartan dose, leading to a 
significant reduction in albuminuria despite small 
BP differences). Based on the recent results of the 
HEAAL study (n=3846) (not discussed previously 
herein because of the lack of a non-losartan 
arm, and the current maximum dose approved 
for losartan is 100 mg/day), increasing losartan 
dosing from 50 mg/day to 150 mg/day in ACEI-
intolerant patients with HF led to a significant 
10% improvement in reduction in the primary 
endpoint of death or HF-related hospitalization 
(43% vs. 46%; P=0.027).125 However, the results 
were influenced by a significant reduction for 
the hospitalization component (13% reduction: 
6.0% vs. 7.0% per 100 patient-years; P=0.025) 
but not for all-cause mortality (6% reduction: 
7.6% vs. 8.2% per 100 patient-years; P=0.24), 
illustrating the complexity of correlating dose 
and long-term outcomes with ARB treatment. 
From a safety standpoint, the higher losartan 
dose resulted in significantly higher incidences 
of renal impairment (7.1% vs. 4.7%; P<0.0001), 
hypotension (2.9% vs. 2.1%; P=0.002), 
hyperkalemia (2.8% vs. 1.9%; P=0.0004), and 
angioedema (0.08% vs. 0%; P=0.03) but not in 
significantly higher treatment discontinuation 
rates attributable to these specific events. 
Accumulating data suggest that using higher-
than-conventional doses of ARB treatment may 
afford renoprotection without producing greater 
BP reductions or affecting the safety/tolerability 
profile, compared with established doses.126-128 
Significant reductions in albuminuria, 
compared with conventional antihypertensive 
dosing, have been reported for irbesartan 
900 mg/day compared with 300 mg/day126 
and valsartan 640 mg/day compared with 
160 mg/day127 (both studies in patients with T2D 
and microalbuminuria, the former of 8 weeks 
and the latter of 30 weeks’ duration) and most 
recently for candesartan 128 mg/day compared 
with 16 mg/day (in patients with diabetes-related 
or diabetes-unrelated persistent proteinuria).128 
Currently, no further studies evaluate the long-
term effects of supramaximal doses of ARBs on 
organ protection or CV morbidity/mortality. As 
the ARBs’ life cycle nears the end, no long-term 
studies are planned.
CONCLUSION
When treating patients, clinicians should 
design a treatment plan that takes into 
consideration all comorbidities/risk factors and 
choose the ARB that is proven effective, based 
on RCTs, in their management. This strategy 
could facilitate the clinicians’ task of managing 
complicated patients, together with providing 
cost savings and better patient compliance.
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APPENDIX: LIST OF CLINICAL TRIAL ACRONYMS
AAA Amlodipine vs. ARB in Atherosclerosis
ADEPT Addition of the AT1 Receptor Antagonist Eprosartan to ACE Inhibitor Therapy in Chronic Heart Failure
AMADEO Telmisartan vs. Losartan in Hypertensive Type 2 Diabetic Patients with Overt Nephropathy
CAPRAF Candesartan in the Prevention of Relapsing Atrial Fibrillation
CASE-J Candesartan Antihypertensive Survival Evaluation in Japan
CATCH Italian Candesartan Assessment in the Treatment of Cardiac Hypertrophy
CENTRO Candesartan on Atherosclerotic Risk Factors
CHARM Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity
CVIP Cardiovascular Irbesartan Project
DETAIL Diabetics Exposed to Telmisartan and Enalapril
DIRECT Diabetic Retinopathy Candesartan Trials
E-COST Efficacy of Candesartan on Outcome in Saitama Trial
ELITE Evaluation of Losartan in the Elderly
EPAS Endothelial Protection, AT1 Blockade and Cholesterol-Dependent Oxidative Stress
EUTOPIA European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis
GISSI-AF Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardio-Atrial Fibrillation
HEAAL Heart Failure Endpoint Evaluation of Angiotensin II Antagonist Losartan
HKVIN Hong Kong Study Using Valsartan in IgA Nephropathy
IDNT Irbesartan Diabetic Nephropathy Trial
IMPROVE Irbesartan in the Management of Proteinuric Patients at High Risk of Vascular Events
INNOVATION Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy
I-PRESERVE Irbesartan in Heart Failure with Preserved Ejection Fraction
IRMA- Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria
ISLAND Irbesartan and Lipoic Acid in Endothelial Dysfunction
JLIGHT Japanese Losartan Therapy Intended for the Global Renal Protection in Hypertensive Patients
LIFE Losartan Intervention for Endpoint Reduction
MARVAL Microalbuminuria Reduction with Valsartan
MITEC Media Intima Thickness Evaluation with Candesartan Cilexetil
MOSES Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention
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NAVIGATOR Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research
ONTARGET Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial
OPTIMAAL Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan
PRoFESS Prevention Regimen for Effectively Avoiding Second Strokes
RENAAL Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan
REPLACE Replacement of Angiotensin-Converting Enzyme Inhibition
RESOLVD Randomized Evaluation of Strategies for Left Ventricular Dysfunction
ROAD Renoprotection of Optimal Antiproteinuric Doses
SCOPE Study on Cognition and Prognosis in the Elderly
SILVHIA Swedish Irbesartan Left Ventricular Hypertrophy Versus Atenolol
SMART Shiga Microalbuminuria Reduction Trial
TRANSCEND Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease
T-VENTURE Inhibitory Effect of Valsartan against Progression of Left Ventricular Dysfunction after Myocardial 
Infarction
VALERIA Valsartan in Combination with Lisinopril in Hypertensive Patients with Microalbuminuria
Val-HeFT Valsartan Heart Failure Trial
VALIANT Valsartan in Acute Myocardial Infarction
VIP Valsartan Inhibits Platelets
VIVALDI Investigate the Efficacy of Telmisartan versus Valsartan in Hypertensive Type 2 Diabetic Patients with 
Overt Nephropathy
